

XPhyto Therapeutics Corp.

09:29 18 Feb 2020

XPhyto Therapeutics starts CBD-infused beverage research with leading German institution

XPhyto Therapeutics Corp (CSE:XPHY) is kicking off its research into cannabis-infused beverages via an exclusive strategic partnership with a leading German research centre.

The cannabis company said Tuesday that its German subsidiary Bunker Pflanzenextrakte GmbH has started work on research and development of cannabis-focused beverages with the chair of the brewing and beverage technology at the Technical University of Munich ("TUM"), School of Life Sciences Weihenstephan.

Vancouver-based XPhyto recently signed a supply, import and distribution agreement for cannabis extracts with an undisclosed cultivator to support its expanding German medicinal marijuana business.

READ: XPhyto Therapeutics brings in C\$2M from placing for European imports business

Weihenstephan is known for the Benedictine Weihenstephan Abbey, which is home to the oldest still-operating brewery in the world and now run by a state-owned firm, Bavarian State Brewery Weihenstephan.

The town is also home to the International Beverage Research Centre (iGZW), an interdisciplinary R&D facility that looks at the entire drink design process from molecular biology through to the final product. The institution has a specific focus on flavor-process-engineering, raw material and product design, food safety, and relevant legislative issues, such as EU designated "novel foods," according to XPhyto.

iGZW's group leader Dr-Ing. Marrtina Gastl said the group was "pleased" to be working with XPhyto on cannabis-based beverages that have "great potential to create opportunities for product innovations" in an increasingly large global market.

Globally-recognized partner

Hugh Rogers, XPhyto's CEO, said the firm was "extremely pleased" to collaborate with a globally recognized partner for the research and development of cannabis-based products and beverages.

"Our recently signed and announced supply, import and distribution agreement for cannabis extracts and isolates with one of the highest quality and largest cannabis cultivators in the world, will ensure the supply of necessary ingredients for all the products developed," said Rogers in a statement.

"Given that XPhyto has been approached by beverage companies in Europe and North America with interest in potential collaboration for the development of cannabis-infused products at Weihenstephan, we are confident that we are on the right track with this exclusive strategic partnership."

Price: 2.69

Market Cap: \$156.05 m

1 Year Share Price Graph



September 2019 March 2020 September 2020

Share Information

Code: XPHY

Listing: CSE

52 week	High	Low
	3.55	0.73

Sector: Cannabis

Website: www.xphyto.com

Company Synopsis:

XPhyto is a science-based cannabis company focused on formulation, clinical validation, and emerging European markets. XPhyto's 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM).

action@proactiveinvestors.com

The firm recently brought in C\$2 million to support its European imports business.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).